Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 12 · above the Ichimoku cloud · RSI 55 · MACD below its signal
None of the 29 investors followed here reported a position in MOREPENLAB.NS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MOREPENLAB.NS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No analyst coverage for this instrument.
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, NASH/ MASH treatment products, CKD treatment, and anti-depressant drugs; and home diagnostic and point-of-care medical devices products, such as blood glucose monitor and test strips, blood pressure monitors, respiratory devices, ortho support, digital thermometers, digital weighing scale, fertility, nebulizers, pulse oximeters, vaporizers, orthopaedic, stethoscope, and miscellaneous products. It also provides OTC healthcare products; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals. In addition, the company offers over the counter products under the Dr. Morepen brand name. Morepen Laboratories Limited was incorporated in 1984 and is based in Gurugram, India.
No recent headlines.
No insider transactions reported for MOREPENLAB.NS.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.6 | 20.3 | -22.9 | 22.8 | 4.5 | 36.7 | -3.5 | 87.9 | 17.6 | 1.9 | +212.5% | ||
| 2025 | -16.8 | -28.7 | 3.2 | 25.8 | 7.8 | -4.7 | -5.4 | -20.2 | 2.6 | -0.6 | -8.8 | -5.4 | −47.5% |
| 2024 | 8.8 | -6.2 | -15.1 | 19.0 | -7.6 | 20.5 | 7.2 | 33.5 | 7.3 | -6.6 | -1.2 | -1.0 | +61.0% |
| 2023 | -23.8 | -12.3 | 2.0 | 6.0 | -6.0 | 18.1 | 2.3 | 25.1 | -4.5 | -10.1 | 37.3 | 6.0 | +28.3% |
| 2022 | -9.1 | -21.1 | -9.4 | 33.0 | -17.2 | -4.1 | -6.6 | -4.4 | -30.8 | 11.7 | 15.2 | 23.3 | −32.7% |
| 2021 | -9.9 | 5.2 | 10.3 | 103.7 | -15.6 | 13.8 | 4.0 | -19.5 | 7.8 | -11.6 | 2.5 | 9.5 | +83.2% |
| 2020 | -5.1 | -16.9 | -22.0 | 91.6 | -12.6 | 44.1 | -0.4 | 21.4 | -12.0 | 3.5 | 15.8 | 4.6 | +97.4% |
| 2019 | -9.5 | -16.5 | 3.0 | -3.5 | 21.3 | -9.9 | -11.0 | -3.4 | 6.7 | -2.4 | -2.5 | -2.2 | −29.8% |
| 2018 | -6.6 | 0.9 | -12.5 | 22.1 | -21.8 | -2.9 | 19.8 | -14.0 | -21.3 | 12.1 | -15.0 | 0.5 | −40.7% |
| 2017 | 1.7 | 1.2 | -9.3 | 9.7 | -6.7 | -3.6 | -1.1 | -11.9 | -2.4 | 3.8 | 36.9 | 64.9 | +83.5% |
| 2016 | -15.1 | -20.5 | 3.1 | -2.7 | -8.0 | 3.2 | -1.4 | -15.7 | 15.9 | 0.4 | 2.1 | -14.9 | −45.9% |
| 2015 | 0.6 | 20.3 | 6.8 | 36.3 | -21.3 | -10.0 | 23.0 | -5.4 | 5.3 | 41.2 | 38.1 | 39.4 | +316.0% |
| 2014 | -8.5 | -1.3 | 2.7 | 7.9 | 23.2 | 2.0 | -14.6 | 67.0 | 72.1 | -4.3 | -19.4 | -7.2 | +120.7% |
| 2013 | -15.2 | -10.4 | -15.0 | 9.8 | -5.4 | -13.2 | -2.2 | 0.0 | 40.0 | 1.6 | -9.4 | 41.4 | +3.8% |
| 2012 | 29.6 | 8.6 | -18.4 | 0.0 | -3.2 | 20.0 | 0.0 | -5.6 | 8.8 | -4.1 | -2.8 | 14.5 | +46.3% |
| 2011 | -17.5 | 4.8 | -1.8 | 3.7 | -9.9 | -8.0 | -2.2 | -12.2 | -2.5 | -3.9 | -14.9 | -14.3 | −57.1% |
| 2010 | -5.3 | -12.3 | -3.8 | 8.6 | -7.3 | 1.3 | -6.5 | -11.1 | 0.8 | -2.3 | -4.0 | 4.1 | −33.3% |
| 2009 | 1.7 | 0.0 | -23.5 | 27.5 | 61.2 | -9.1 | -4.1 | 6.7 | -1.7 | -14.0 | 18.4 | 8.6 | +61.5% |
| 2008 | 0.0 | -53.7 | -20.2 | 21.1 | -11.1 | -16.5 | 6.6 | -7.0 | -22.7 | -22.1 | -16.5 | 10.4 | −81.8% |
| 2007 | 62.7 | -17.4 | -4.0 | -10.8 | 15.3 | -8.6 | -9.5 | 2.6 | 22.0 | -20.4 | 6.2 | 98.1 | +130.1% |